<DOC>
	<DOCNO>NCT02767765</DOCNO>
	<brief_summary>This study evaluate efficacy tolerability subcutaneous ( SC ) intramuscular ( IM ) recombinant human erythropoietin beta ( r-HuEPO ) participant anemia histologically cytologically confirm cancer .</brief_summary>
	<brief_title>A Study Recombinant Human Erythropoietin Beta ( NeoRecormon ) Anemic Cancer Participants Treated With Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Histological cytological confirm cancer Participants treat least first line chemotherapy Hemoglobin le ( &lt; ) 11 gram per deciliter ( g/dL ) Participants able receive iron supplement , necessary History hypersensitivity active inactive excipients rHuEPO Insufficient controllable hypertension Thalassemic syndromes Anemia cause hematic loss Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>